The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore. Methods: In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013–2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types. Results: A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001). Conclusion: In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.
Abstract
Background/Aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore. Methods: In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013–2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types. Results: A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001). Conclusion: In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.
참고문헌 (50)
- Hyung Joon Yim, "Elimination of hepatitis C: What would be the practical approach?", Clinical and Molecular Hepatology, 27(1), pp.97~99 (2021), 대한간학회[DOI]
- Chung-Feng Huang, "Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy", Clinical and Molecular Hepatology, 26(3), pp.251~260 (2020), 대한간학회[DOI]
- Gallacher J, "Progress towards micro-elimination of hepatitis C in the custodial setting", J Viral Hepat, 28, pp.300~301 (2021)
- "World prison population list. Twelve editions"[URL]
- "Singapore Prison Service Annual Report 2019"[URL]
- Hsiang JC, "Point-of-care hepatitis C screening with direct access referral to improve linkage of care among people with substance misuse: a pilot randomised study", Singapore Med J. (2020)[DOI]
- Moazen B, "Prevalence of drug injection, sexual activity, tattooing, and piercing among prison inmates", Epidemiol Rev, 40, pp.58~69 (2018)
- Ruiz JD, "Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system", West J Med, 170, pp.156~160 (1999)
- Stone J, "Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs : a systematic review and metaanalysis", Lancet Infect Dis, 18, pp.1397~1409 (2018)
- Fox RK, "Hepatitis C virus infection among prisoners in the California state correctional system", Clin Infect Dis, 41, pp.177~186 (2005)
- World Health Organization, "Guidelines for the Care and Treatment of persons diagnosed with chronic hepatitis C virus infection" (2018), World Health Organization
- Lafferty L, "Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison", J Viral Hepat, 25, pp.1526~1532 (2018)
- Crowley D, "Hepatitis C virus screening and treatment in Irish prisons from a governor and prison officer perspective-a qualitative exploration", Health Justice, 6, pp.23~ (2018)
- Aspinall EJ, "A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy", J Viral Hepat, 23, pp.1009~1016 (2016)
- Enkelmann J, "High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014 : missed opportunities for hepatitis C testing", Harm Reduct J, 17, pp.7~ (2020)
- Wong YJ, "Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore", JGH Open, 3, pp.210~216 (2019)
- "Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C. Technology guidance from the MOH drug advisory committee"[URL]
- Papaluca T, "Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care", J Hepatol, 70, pp.839~846 (2019)
- Yang TH, "Microelimination of chronic hepatitis C by universal screening plus directacting antivirals for incarcerated persons in Taiwan", Open Forum Infect Dis (2020)
- Giuliani R, "HCV micro-elimination in two prisons in Milan, Italy : a model of care", J Viral Hepat, 27, pp.1444~1454 (2020)
- Cuadrado A, "Microenvironment eradication of hepatitis C : a novel treatment paradigm", Am J Gastroenterol, 113, pp.1639~1648 (2018)
- Hariri S, "Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era", Harm Reduct J, 17, pp.80~ (2020)
- Overton K, "Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting", Int J Drug Policy, 72, pp.123~128 (2019)
- Chan J, "The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017", EClinicalMedicine, 27, pp.100567~ (2020)
- Wong YJ, "Efficacy and safety of sofosbuvir", velpatasvir in a real-world chronic hepatitis C genotype 3 cohort, 2021, pp.36, 1300~1308
- "Recommendations for testing, managing, and treating hepatitis C"[URL]
- European Association for Study of Liver, "EASL-ALEH clinical practice guidelines:non-invasive tests for evaluation of liver disease severity and prognosis", J Hepatol, 63, pp.237~264 (2015)
- Talal AH, "Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C : results from a US database of over 45 000 HCV-infected, evaluated patients", Aliment Pharmacol Ther, 37, pp.473~481 (2013)
- Chaillon A, "What is required for achieving hepatitis C virus elimination in Singapore? A modeling study", J Gastroenterol Hepatol, 36, pp.1110~1117 (2021)
- Beckman AL, "New hepatitis C drugs are very costly and unavailable to many state prisoners", Health Aff(Millwood), 35, pp.1893~1901 (2016)
- Bartlett SR, "Demonstration of near-elimination of hepatitis C virus among a prison pulation : the lotus glen correctional centre hepatitis C treatment project", Clin Infect Dis, 67, pp.460~463 (2018)
- Marshall AD, "The removal of DAA restrictions in Europe-one step closer to eliminating HCV as a major public health threat", J Hepatol, 69, pp.1188~1196 (2018)
- Pontali E, "Treatment with direct-acting antivirals in a multicenter cohort of HCV-infected inmates in Italy", Int J Drug Policy, 59, pp.50~53 (2018)
- Martin NK, "Prioritization of HCV treatment in the direct-acting antiviral era : an economic evaluation", J Hepatol, 65, pp.17~25 (2016)
- Ocal S, "Addressing hepatitis C in the American incarcerated population : strategies for Nationwide elimination", Curr HIV, 2020, pp.17, 18~25
- Fiore V, "HCV testing and treatment initiation in an Italian prison setting : a step-by-step model to micro-eliminate hepatitis C", Int J Drug Policy, 90, pp.103055~ (2021)
- Hochstatter KR, "The continuum of hepatitis C care for criminal justice involved adults in the DAA era : a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care", Health Justice, 5, pp.10~ (2017)
- Allen SA, "Treatment of chronic hepatitis C in a state correctional facility", Ann Intern Med, 138, pp.187~190 (2003)
- Bate JP, "High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C", J Gastroenterol Hepatol, 25, pp.1276~1280 (2010)
- Boonwaat L, "Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C", Med J Aust, 192, pp.496~500 (2010)
- Chew KW, "Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C", J Clin Gastroenterol, 43, pp.686~691 (2009)
- Juan Jd, "Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population(EPIBAND study)", Eur J Gastroenterol Hepatol, 26, pp.1083~1089 (2014)
- Farley J, "Feasibility and outcome of HCV treatment in a Canadian federal prison population", Am J Public Health, 95, pp.1737~1739 (2005)
- Iacomi F, "HCV infected prisoners : should they be still considered a difficult to treat population?", BMC Infect Dis, 13, pp.374~ (2013)
- Lloyd AR, "Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting", Clin Infect Dis, 56, pp.1078~1084 (2013)
- Maru DS, "Clinical outcomes of hepatitis C treatment in a prison setting : feasibility and effectiveness for challenging treatment populations", Clin Infect Dis, 47, pp.952~961 (2008)
- Rice JP, "Comparison of hepatitis C virus treatment between incarcerated and community patients", Hepatology, 56, pp.1252~1260 (2012)
- Saiz de la Hoya P, "Directly observed therapy for chronic hepatitis C : a randomized clinical trial in the prison setting", Gastroenterol Hepatol, 37, pp.443~451 (2014)
- Simonović Babić J, "Antiviral treatment of hepatitis C in serbian prison setting : medical treatment outcomes and patients’ adherence", Med Pregl, 69, pp.85~91 (2016)
- Strock P, "Access to treatment of hepatitis C in prison inmates", Dig Dis Sci, 54, pp.1325~1330 (2009)